US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Incyte

92.23

+1.611.78%

Post-market: 92.230.00000.00%19:45 EDT

Volume:1.06M

Turnover:97.48M

Market Cap:18.36B

PE:14.39

High:93.83

Open:91.00

Low:91.00

Close:90.62

52wk High:112.29

52wk Low:53.56

Shares:199.01M

Float Shares:163.04M

Volume Ratio:0.51

T/O Rate:0.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.41

EPS(LYR):6.41

ROE:29.87%

ROA:13.57%

PB:3.55

PE(LYR):14.39

Loading ...

Overview Company News Filings

Japan Approves Incyte's Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma

Incyte Japan Announces Approval of Minjuvi® (Tafasitamab) in Combination With Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

THOMSON REUTERS

Japan Approves Incyte’s Zynyz as First-Line Treatment for Advanced Anal Cancer

Incyte Japan Announces Approval of Zynyz® (Retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

THOMSON REUTERS

Weekly Winners｜SanDisk, Moderna Rocket Around 15% Each; Carnival Rises over 12%; Micron Rallies More Than 10%; AppLovin Gains 7%

Tiger Newspress

Incyte Corp. Stock Advances 5.5%, Outperforms Peers

First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY)

Simply Wall St.

Incyte EVP Michael James Morrissey Reports Sale of Common Shares

BRIEF-Incyte Announces European Commission Approval Of Minjuvi (Tafasitamab)

BUZZ-Incyte up after European Commission expands use of cancer drug

EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma

Incyte Announces European Commission Approval of Minjuvi® (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

THOMSON REUTERS

Incyte Corp. Stock Advances 3.4%, Outperforms Peers

Incyte EVP & Chief Scientific Officer Patrick A. Mayes Reports Disposal of Common Shares

Incyte: on December 10, , HervÉ Hoppenot Notified That He Was Retiring From the Company’s Board of Directors, Effective Immediately

THOMSON REUTERS

Incyte Announces Resignation of Board Member Hervé Hoppenot

Incyte Announces Change to Its Board of Directors

THOMSON REUTERS

Incyte's Blood Cancer Drug Program 'Looks Very Viable' Amid Development Challenges, RBC Says

MT Newswires Live

Why Incyte (INCY) Is Down 6.2% After Breakthrough Status for INCA033989 And Promising Phase 1 Data

Simply Wall St.

Incyte Presents Updated Positive Data at Ash 2025 Reinforcing the Potential of Inca033989, Its First-in-Class Mutcalr-Targeted Monoclonal Antibody, in Patients With Essential Thrombocythemia

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INCY/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INCY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INCY\",,,,,undefined,":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"Incyte","latestPrice":92.23,"timestamp":1774468800000,"preClose":90.62,"halted":0,"volume":1055736,"hourTrading":{"tag":"盘后","latestPrice":92.23,"preClose":92.23,"latestTime":"19:45 EDT","volume":42509,"amount":3920382.1842,"timestamp":1774482303231,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01776649746192893,"floatShares":163042517,"shares":199014486,"eps":6.41,"marketStatus":"Not Yet Opened","change":1.61,"latestTime":"03-25 16:00:00 EDT","open":91,"high":93.83,"low":91,"amount":97475583.346416,"amplitude":0.031229,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.41,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774512000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":90.62,"preHourTrading":{"tag":"盘前","latestPrice":91.11,"preClose":90.62,"latestTime":"09:25 EDT","volume":557,"amount":50803.799558,"timestamp":1774445110036,"change":0.49,"changeRate":0.005407,"amplitude":0.025381},"postHourTrading":{"tag":"盘后","latestPrice":92.23,"preClose":92.23,"latestTime":"19:45 EDT","volume":42509,"amount":3920382.1842,"timestamp":1774482303231,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.512615,"impliedVol":0.3844,"impliedVolPercentile":0.52},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INCY\",,,,,undefined,":{"symbol":"INCY","floatShares":163042517,"roa":"13.57%","roe":"29.87%","lyrEps":6.41,"volumeRatio":0.512615,"shares":199014486,"dividePrice":0,"high":93.83,"amplitude":0.031229,"preClose":90.62,"low":91,"week52Low":53.56,"pbRate":"3.55","psRate":"3.57","week52High":112.29,"institutionHeld":0.9169,"latestPrice":92.23,"eps":6.41,"divideRate":0,"volume":1055736,"delay":0,"ttmEps":6.41,"open":91,"prevYearClose":98.77,"prevWeekClose":90.78,"prevMonthClose":101.27,"prevQuarterClose":98.77,"fiveDayClose":92.24,"twentyDayClose":99.98,"sixtyDayClose":100.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INCY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-10","symbol":"INCY","fiscalQuarterEnding":"2025/12","expectedEps":1.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1770699600000,"reportTimeType":"pre","actualEps":1.09},{"market":"US","date":"2025-10-28","symbol":"INCY","fiscalQuarterEnding":"2025/09","expectedEps":1.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1761624000000,"reportTimeType":"pre","actualEps":2.03},{"market":"US","date":"2025-07-29","symbol":"INCY","fiscalQuarterEnding":"2025/06","expectedEps":1.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753761600000,"reportTimeType":"pre","actualEps":1.31},{"market":"US","date":"2025-04-29","symbol":"INCY","fiscalQuarterEnding":"2025/03","expectedEps":0.75,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"pre","actualEps":0.89},{"market":"US","date":"2025-02-10","symbol":"INCY","fiscalQuarterEnding":"2024/12","expectedEps":1.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1739163600000,"reportTimeType":"pre","actualEps":1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INCY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INCY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.1852,"hold":0.5556,"sell":0.037,"strongSell":0,"meanLabel":"BUY","meanPercent":0.1852,"analysts":27,"updateTime":1773633600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INCY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INCY","date":"2026-03-24","current":14.388456,"percent":0.022801,"low":-63.658612,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"high":648.145308,"avg":97.45749,"sd":165.050382,"marketCap":18000860258},"quantilePoints":[{"date":"2021-03-26","current":-60.779128,"twenty":-145.501961,"median":-57.535851,"eighty":138.728728,"marketCap":17972205879},{"date":"2021-04-01","current":-61.715907,"twenty":-144.624845,"median":-57.535851,"eighty":138.728728,"marketCap":18249208685},{"date":"2021-04-09","current":-59.448307,"twenty":-143.480065,"median":-57.511438,"eighty":138.728728,"marketCap":17578686020},{"date":"2021-04-16","current":-61.470561,"twenty":-142.437133,"median":-57.511438,"eighty":138.728728,"marketCap":18176660331},{"date":"2021-04-23","current":-63.636305,"twenty":-140.864214,"median":-57.511438,"eighty":138.728728,"marketCap":18817064417},{"date":"2021-04-30","current":-63.487587,"twenty":-139.050719,"median":-57.511438,"eighty":138.728728,"marketCap":18773089038},{"date":"2021-05-07","current":38.029737,"twenty":-138.140751,"median":-57.417418,"eighty":138.728728,"marketCap":18196468486},{"date":"2021-05-14","current":37.974581,"twenty":-137.538187,"median":-57.041687,"eighty":138.728728,"marketCap":18170077669},{"date":"2021-05-21","current":38.038929,"twenty":-136.154034,"median":-56.859827,"eighty":138.728728,"marketCap":18200866956},{"date":"2021-05-28","current":38.507751,"twenty":-134.962092,"median":-56.671737,"eighty":138.728728,"marketCap":18425188903},{"date":"2021-06-04","current":38.300918,"twenty":-134.368461,"median":-56.473605,"eighty":138.728728,"marketCap":18326223338},{"date":"2021-06-11","current":37.956196,"twenty":-133.781698,"median":-56.211759,"eighty":138.728728,"marketCap":18161280730},{"date":"2021-06-18","current":38.590485,"twenty":-133.212304,"median":-55.917182,"eighty":138.728728,"marketCap":18464775128},{"date":"2021-06-25","current":39.909621,"twenty":-131.986896,"median":-55.561887,"eighty":138.728728,"marketCap":19095955507},{"date":"2021-07-02","current":38.415826,"twenty":-131.334231,"median":-55.337977,"eighty":138.728728,"marketCap":18381204207},{"date":"2021-07-09","current":37.707996,"twenty":-130.920252,"median":-54.86823,"eighty":138.728728,"marketCap":18042522053},{"date":"2021-07-16","current":36.002771,"twenty":-129.331126,"median":-54.431207,"eighty":138.728728,"marketCap":17226605953},{"date":"2021-07-23","current":36.448612,"twenty":-128.489296,"median":-54.267553,"eighty":138.728728,"marketCap":17439931726},{"date":"2021-07-30","current":35.552334,"twenty":-127.966687,"median":-54.053184,"eighty":138.728728,"marketCap":17011080945},{"date":"2021-08-06","current":49.904723,"twenty":-127.053631,"median":-53.781502,"eighty":138.728728,"marketCap":16849731024},{"date":"2021-08-13","current":48.053736,"twenty":-126.920152,"median":-53.75838,"eighty":137.245403,"marketCap":16224767213},{"date":"2021-08-20","current":48.98904,"twenty":-126.920152,"median":-53.75838,"eighty":135.125566,"marketCap":16540561648},{"date":"2021-08-27","current":49.499207,"twenty":-126.920152,"median":-53.75838,"eighty":133.981527,"marketCap":16712813157},{"date":"2021-09-03","current":49.767371,"twenty":-126.920152,"median":-53.75838,"eighty":132.851508,"marketCap":16803355618},{"date":"2021-09-10","current":46.516696,"twenty":-126.920152,"median":-53.75838,"eighty":131.356968,"marketCap":15705804331},{"date":"2021-09-17","current":49.701965,"twenty":-126.920152,"median":-53.75838,"eighty":73.50992,"marketCap":16781272091},{"date":"2021-09-24","current":45.130091,"twenty":-126.920152,"median":-53.75838,"eighty":72.160274,"marketCap":15237633561},{"date":"2021-10-01","current":44.613384,"twenty":-126.920152,"median":-53.75838,"eighty":71.599051,"marketCap":15063173698},{"date":"2021-10-08","current":43.095966,"twenty":-126.920152,"median":-53.75838,"eighty":70.390135,"marketCap":14550835874},{"date":"2021-10-15","current":42.880127,"twenty":-126.920152,"median":-53.75838,"eighty":69.308384,"marketCap":14477960235},{"date":"2021-10-22","current":43.03056,"twenty":-126.920152,"median":-53.75838,"eighty":68.891282,"marketCap":14528752347},{"date":"2021-10-29","current":43.808891,"twenty":-126.920152,"median":-53.75838,"eighty":68.326669,"marketCap":14791546317},{"date":"2021-11-05","current":28.040026,"twenty":-126.321891,"median":-53.279085,"eighty":68.258847,"marketCap":14989637337},{"date":"2021-11-12","current":27.110317,"twenty":-125.553074,"median":-52.997601,"eighty":68.258847,"marketCap":14492633446},{"date":"2021-11-19","current":26.655793,"twenty":-125.039639,"median":-47.426815,"eighty":68.258847,"marketCap":14249653767},{"date":"2021-11-26","current":28.254893,"twenty":-123.924854,"median":-46.283755,"eighty":68.258847,"marketCap":15104500458},{"date":"2021-12-03","current":27.180562,"twenty":-122.424514,"median":-43.300979,"eighty":68.258847,"marketCap":14530184852},{"date":"2021-12-10","current":27.023544,"twenty":-120.541483,"median":-41.894137,"eighty":68.258847,"marketCap":14446246417},{"date":"2021-12-17","current":30.118443,"twenty":-119.13698,"median":26.841735,"eighty":68.258847,"marketCap":16100717146},{"date":"2021-12-23","current":30.358101,"twenty":-115.775745,"median":26.911979,"eighty":68.258847,"marketCap":16228833704},{"date":"2021-12-31","current":30.329177,"twenty":-112.581547,"median":27.15577,"eighty":68.258847,"marketCap":16213371361},{"date":"2022-01-07","current":30.242404,"twenty":-111.158033,"median":27.511125,"eighty":68.252065,"marketCap":16166984331},{"date":"2022-01-14","current":30.940719,"twenty":-109.706662,"median":27.854084,"eighty":68.252065,"marketCap":16540289475},{"date":"2022-01-21","current":30.90353,"twenty":-109.122909,"median":28.14746,"eighty":68.252065,"marketCap":16520409320},{"date":"2022-01-28","current":30.672136,"twenty":-107.744794,"median":29.62673,"eighty":68.252065,"marketCap":16396710574},{"date":"2022-02-04","current":30.035802,"twenty":-106.666568,"median":30.077123,"eighty":68.252065,"marketCap":16056539022},{"date":"2022-02-11","current":15.576603,"twenty":-105.677621,"median":30.151499,"eighty":68.252065,"marketCap":14775669617},{"date":"2022-02-18","current":15.989584,"twenty":-103.869131,"median":30.151499,"eighty":68.252065,"marketCap":15167415202},{"date":"2022-02-25","current":15.963918,"twenty":-103.539483,"median":30.151499,"eighty":68.252065,"marketCap":15143069431},{"date":"2022-03-04","current":16.344234,"twenty":-102.763434,"median":30.151499,"eighty":68.252065,"marketCap":15503829489},{"date":"2022-03-11","current":17.251858,"twenty":-101.447128,"median":30.151499,"eighty":68.252065,"marketCap":16364784474},{"date":"2022-03-18","current":17.545844,"twenty":-100.506256,"median":30.151499,"eighty":68.252065,"marketCap":16643654212},{"date":"2022-03-25","current":18.306475,"twenty":-99.373088,"median":30.151499,"eighty":68.252065,"marketCap":17365174328},{"date":"2022-04-01","current":18.651792,"twenty":-97.445558,"median":30.151499,"eighty":68.252065,"marketCap":17692735608},{"date":"2022-04-08","current":19.407757,"twenty":-93.439406,"median":30.151499,"eighty":68.252065,"marketCap":18409829221},{"date":"2022-04-14","current":19.071772,"twenty":-91.423658,"median":30.151499,"eighty":68.252065,"marketCap":18091120948},{"date":"2022-04-22","current":17.867829,"twenty":-89.542294,"median":30.151499,"eighty":68.252065,"marketCap":16949082973},{"date":"2022-04-29","current":17.489847,"twenty":-88.994619,"median":30.151499,"eighty":68.252065,"marketCap":16590536167},{"date":"2022-05-06","current":17.838131,"twenty":-88.883056,"median":30.023406,"eighty":68.021473,"marketCap":16643654212},{"date":"2022-05-13","current":17.781404,"twenty":-88.883056,"median":29.345751,"eighty":67.499248,"marketCap":16590725323},{"date":"2022-05-20","current":17.776656,"twenty":-88.883056,"median":28.029696,"eighty":66.763386,"marketCap":16586295223},{"date":"2022-05-27","current":18.325054,"twenty":-88.883056,"median":27.587568,"eighty":65.832537,"marketCap":17097971799},{"date":"2022-06-03","current":17.558246,"twenty":-88.883056,"median":27.482201,"eighty":65.113631,"marketCap":16382510613},{"date":"2022-06-10","current":16.713095,"twenty":-88.883056,"median":27.06693,"eighty":64.292991,"marketCap":15593952774},{"date":"2022-06-17","current":16.919635,"twenty":-88.883056,"median":26.885121,"eighty":60.086945,"marketCap":15786662133},{"date":"2022-06-24","current":18.562456,"twenty":-88.883056,"median":26.36655,"eighty":58.867713,"marketCap":17319476810},{"date":"2022-07-01","current":18.439007,"twenty":-88.883056,"median":19.147526,"eighty":58.036609,"marketCap":17204294204},{"date":"2022-07-08","current":19.106106,"twenty":-88.883056,"median":19.102104,"eighty":57.517697,"marketCap":17826723285},{"date":"2022-07-15","current":18.999276,"twenty":-88.883056,"median":18.925681,"eighty":56.936909,"marketCap":17727046030},{"date":"2022-07-22","current":19.205815,"twenty":-88.883056,"median":18.904315,"eighty":56.208463,"marketCap":17919755389},{"date":"2022-07-29","current":18.441381,"twenty":-88.883056,"median":18.878115,"eighty":55.366109,"marketCap":17206509254},{"date":"2022-08-05","current":16.913825,"twenty":-88.883056,"median":18.721515,"eighty":55.122825,"marketCap":15983801593},{"date":"2022-08-12","current":17.415237,"twenty":-88.883056,"median":18.588795,"eighty":54.717821,"marketCap":16457642683},{"date":"2022-08-19","current":17.544692,"twenty":-88.883056,"median":18.439007,"eighty":54.475943,"marketCap":16579979532},{"date":"2022-08-26","current":16.824451,"twenty":-88.883056,"median":18.331526,"eighty":53.5014,"marketCap":15899341789},{"date":"2022-09-02","current":16.525528,"twenty":-88.883056,"median":18.243478,"eighty":52.597171,"marketCap":15616854883},{"date":"2022-09-09","current":16.99392,"twenty":-88.883056,"median":18.047294,"eighty":52.079665,"marketCap":16059491847},{"date":"2022-09-16","current":16.200713,"twenty":-88.883056,"median":17.954707,"eighty":50.829148,"marketCap":15309900607},{"date":"2022-09-23","current":15.74409,"twenty":-88.883056,"median":17.867829,"eighty":50.44787,"marketCap":14878385175},{"date":"2022-09-30","current":15.685246,"twenty":-88.883056,"median":17.800396,"eighty":50.239968,"marketCap":14822777516},{"date":"2022-10-07","current":16.10421,"twenty":-88.883056,"median":17.744168,"eighty":50.010331,"marketCap":15218704046},{"date":"2022-10-14","current":16.264264,"twenty":-88.883056,"median":17.643549,"eighty":49.808517,"marketCap":15369956878},{"date":"2022-10-21","current":16.612615,"twenty":-88.883056,"median":17.544692,"eighty":49.590775,"marketCap":15699154218},{"date":"2022-10-28","current":17.558814,"twenty":-88.883056,"median":17.448189,"eighty":49.403714,"marketCap":16593325371},{"date":"2022-11-04","current":19.630562,"twenty":-88.883056,"median":17.448189,"eighty":49.110861,"marketCap":17197353676},{"date":"2022-11-11","current":19.688971,"twenty":-88.883056,"median":17.448189,"eighty":48.910553,"marketCap":17248523034},{"date":"2022-11-18","current":19.668655,"twenty":-88.883056,"median":17.448189,"eighty":48.59263,"marketCap":17230724996},{"date":"2022-11-25","current":19.874357,"twenty":-88.883056,"median":17.448189,"eighty":48.454449,"marketCap":17410930125},{"date":"2022-12-02","current":21.111107,"twenty":-88.883056,"median":17.448189,"eighty":48.041963,"marketCap":18494385654},{"date":"2022-12-09","current":20.910485,"twenty":-88.883056,"median":17.448189,"eighty":47.59851,"marketCap":18318630035},{"date":"2022-12-16","current":20.831759,"twenty":-88.883056,"median":17.448189,"eighty":47.263641,"marketCap":18249662640},{"date":"2022-12-23","current":20.661611,"twenty":-88.883056,"median":17.448189,"eighty":47.016101,"marketCap":18100604076},{"date":"2022-12-30","current":20.3975,"twenty":-88.883056,"median":17.448189,"eighty":46.554796,"marketCap":17869229589},{"date":"2023-01-06","current":20.537174,"twenty":-88.211139,"median":17.541628,"eighty":46.554796,"marketCap":17991591097},{"date":"2023-01-13","current":20.527016,"twenty":-87.440338,"median":17.558814,"eighty":46.554796,"marketCap":17982692078},{"date":"2023-01-20","current":21.128884,"twenty":-86.920554,"median":17.688817,"eighty":46.554796,"marketCap":18509958937},{"date":"2023-01-27","current":21.763766,"twenty":-86.375415,"median":17.776656,"eighty":46.554796,"marketCap":19066147607},{"date":"2023-02-03","current":21.233005,"twenty":-85.224284,"median":17.831258,"eighty":46.554796,"marketCap":18601173879},{"date":"2023-02-10","current":51.876379,"twenty":-84.628433,"median":17.926219,"eighty":47.016101,"marketCap":17672207326},{"date":"2023-02-17","current":51.706207,"twenty":-84.430663,"median":18.016432,"eighty":47.263641,"marketCap":17614236422},{"date":"2023-02-24","current":50.410279,"twenty":-84.430663,"median":18.075782,"eighty":47.465954,"marketCap":17172765686},{"date":"2023-03-03","current":50.763714,"twenty":-84.430663,"median":18.306475,"eighty":47.986899,"marketCap":17293166796},{"date":"2023-03-10","current":47.131189,"twenty":-84.430663,"median":18.365412,"eighty":48.204376,"marketCap":16055710946},{"date":"2023-03-17","current":48.184949,"twenty":-84.430663,"median":18.530464,"eighty":48.335268,"marketCap":16414684625},{"date":"2023-03-24","current":45.966163,"twenty":-84.430663,"median":18.651792,"eighty":48.401919,"marketCap":15658833214},{"date":"2023-03-31","current":47.301362,"twenty":-84.412914,"median":18.778445,"eighty":48.397883,"marketCap":16113681850},{"date":"2023-04-06","current":48.28967,"twenty":-84.412914,"median":18.882782,"eighty":48.397883,"marketCap":16450359028},{"date":"2023-04-14","current":49.304159,"twenty":-84.430663,"median":19.071772,"eighty":48.454449,"marketCap":16795954805},{"date":"2023-04-21","current":48.335486,"twenty":-84.430663,"median":19.139343,"eighty":48.50111,"marketCap":16465966579},{"date":"2023-04-28","current":48.204584,"twenty":-84.430663,"median":19.205815,"eighty":48.553797,"marketCap":16421373575},{"date":"2023-05-05","current":45.522611,"twenty":-84.430663,"median":19.457874,"eighty":48.598963,"marketCap":14766214974},{"date":"2023-05-12","current":44.133343,"twenty":-84.430663,"median":19.577232,"eighty":48.598963,"marketCap":14315576596},{"date":"2023-05-19","current":43.761954,"twenty":-65.975243,"median":19.668655,"eighty":48.598963,"marketCap":14195108910},{"date":"2023-05-26","current":43.239259,"twenty":-63.609535,"median":19.757538,"eighty":48.598963,"marketCap":14025561798},{"date":"2023-06-02","current":42.30391,"twenty":-63.241519,"median":19.876896,"eighty":48.598963,"marketCap":13722161702},{"date":"2023-06-09","current":42.30391,"twenty":-62.97873,"median":20.184179,"eighty":48.598963,"marketCap":13722161702},{"date":"2023-06-16","current":43.03981,"twenty":-62.654259,"median":20.2337,"eighty":48.609617,"marketCap":13960866189},{"date":"2023-06-23","current":42.579013,"twenty":-62.203628,"median":20.44829,"eighty":48.620272,"marketCap":13811397024},{"date":"2023-06-30","current":42.537748,"twenty":-61.715907,"median":20.562569,"eighty":48.630926,"marketCap":13798011726},{"date":"2023-07-07","current":43.232382,"twenty":-61.507591,"median":20.746685,"eighty":48.630926,"marketCap":14023330915},{"date":"2023-07-14","current":42.599646,"twenty":-61.285022,"median":20.93842,"eighty":48.630926,"marketCap":13818089673},{"date":"2023-07-21","current":44.023302,"twenty":-60.953261,"median":21.128884,"eighty":48.639436,"marketCap":14279882467},{"date":"2023-07-28","current":43.108586,"twenty":-60.731546,"median":21.301572,"eighty":48.639436,"marketCap":13983175020},{"date":"2023-08-04","current":39.731882,"twenty":-60.438616,"median":21.456483,"eighty":48.639436,"marketCap":14561218421},{"date":"2023-08-11","current":40.05595,"twenty":-60.194533,"median":21.842492,"eighty":48.639436,"marketCap":14679984899},{"date":"2023-08-18","current":39.261068,"twenty":-59.937514,"median":26.841735,"eighty":48.639436,"marketCap":14388670895},{"date":"2023-08-25","current":39.273297,"twenty":-59.653506,"median":26.936772,"eighty":48.639436,"marketCap":14393152649},{"date":"2023-09-01","current":39.456731,"twenty":-59.512326,"median":27.180562,"eighty":48.639436,"marketCap":14460378958},{"date":"2023-09-08","current":38.796367,"twenty":-59.369499,"median":27.531785,"eighty":48.639436,"marketCap":14218364247},{"date":"2023-09-15","current":38.814711,"twenty":-59.210021,"median":27.887141,"eighty":48.639436,"marketCap":14225086878},{"date":"2023-09-22","current":35.959249,"twenty":-58.96037,"median":28.341665,"eighty":48.639436,"marketCap":13178597342},{"date":"2023-09-29","current":35.83696,"twenty":-58.783922,"median":29.746559,"eighty":48.639436,"marketCap":13133779803},{"date":"2023-10-06","current":35.959249,"twenty":-58.648658,"median":30.184555,"eighty":48.639436,"marketCap":13178597342},{"date":"2023-10-13","current":34.589606,"twenty":-58.325093,"median":30.329177,"eighty":48.639436,"marketCap":12676640906},{"date":"2023-10-20","current":34.020959,"twenty":-58.123791,"median":30.432478,"eighty":48.639436,"marketCap":12468239349},{"date":"2023-10-23","current":33.709121,"twenty":-58.104138,"median":30.444874,"eighty":48.639436,"marketCap":12353954625},{"date":"2023-11-03","current":28.460509,"twenty":-57.44054,"median":30.568835,"eighty":48.673477,"marketCap":12095175574},{"date":"2023-11-10","current":27.695867,"twenty":-57.041687,"median":30.568835,"eighty":48.673477,"marketCap":11770217179},{"date":"2023-11-17","current":28.471056,"twenty":-56.859827,"median":30.568835,"eighty":48.673477,"marketCap":12099657759},{"date":"2023-11-24","current":28.339221,"twenty":-56.671737,"median":30.568835,"eighty":48.673477,"marketCap":12043630450},{"date":"2023-12-01","current":28.655625,"twenty":-56.44742,"median":30.568835,"eighty":48.673477,"marketCap":12178095992},{"date":"2023-12-08","current":29.09859,"twenty":-55.919657,"median":30.566769,"eighty":48.664967,"marketCap":12366347752},{"date":"2023-12-15","current":33.665349,"twenty":-55.635877,"median":30.642536,"eighty":48.664967,"marketCap":14307133753},{"date":"2023-12-22","current":32.531569,"twenty":-55.314549,"median":30.804361,"eighty":48.664967,"marketCap":13825298892},{"date":"2023-12-29","current":33.080002,"twenty":-54.86823,"median":30.90353,"eighty":48.673477,"marketCap":14058372499},{"date":"2024-01-05","current":35.115533,"twenty":-54.444299,"median":31.099803,"eighty":48.675257,"marketCap":14923434158},{"date":"2024-01-12","current":33.280391,"twenty":-54.278027,"median":32.355824,"eighty":48.675257,"marketCap":14143534010},{"date":"2024-01-19","current":32.262626,"twenty":-54.097036,"median":32.479514,"eighty":48.677037,"marketCap":13711003180},{"date":"2024-01-26","current":32.125518,"twenty":-53.861692,"median":32.505541,"eighty":48.675257,"marketCap":13652734778},{"date":"2024-02-02","current":31.197401,"twenty":-53.506891,"median":32.505541,"eighty":48.675257,"marketCap":13258302520},{"date":"2024-02-09","current":30.24819,"twenty":-53.144235,"median":32.505541,"eighty":48.675257,"marketCap":12854905891},{"date":"2024-02-16","current":22.155837,"twenty":-52.564683,"median":32.440893,"eighty":48.588308,"marketCap":13240305768},{"date":"2024-02-23","current":22.884721,"twenty":-52.564683,"median":32.304813,"eighty":48.499532,"marketCap":13675886456},{"date":"2024-03-01","current":21.926651,"twenty":-52.492457,"median":32.083331,"eighty":48.414027,"marketCap":13103344830},{"date":"2024-03-08","current":22.178379,"twenty":-52.492457,"median":31.44525,"eighty":48.309305,"marketCap":13253777335},{"date":"2024-03-15","current":21.99428,"twenty":-52.492457,"median":30.994435,"eighty":48.204584,"marketCap":13143759533},{"date":"2024-03-22","current":21.686194,"twenty":-52.492457,"median":30.891134,"eighty":48.099863,"marketCap":12959648108},{"date":"2024-03-28","current":21.460766,"twenty":-52.492457,"median":30.738249,"eighty":47.955422,"marketCap":12824932431},{"date":"2024-04-05","current":20.660496,"twenty":-52.564683,"median":30.61994,"eighty":47.58148,"marketCap":12346691778},{"date":"2024-04-12","current":20.634196,"twenty":-52.564683,"median":30.4676,"eighty":47.410327,"marketCap":12330974949},{"date":"2024-04-19","current":19.845197,"twenty":-52.564683,"median":30.368431,"eighty":47.294817,"marketCap":11859470080},{"date":"2024-04-26","current":19.229027,"twenty":-52.492457,"median":30.308517,"eighty":47.22407,"marketCap":11491247231},{"date":"2024-05-03","current":15.991635,"twenty":-52.492457,"median":30.184555,"eighty":46.833129,"marketCap":11920868470},{"date":"2024-05-10","current":16.115134,"twenty":-52.492457,"median":29.750691,"eighty":46.53527,"marketCap":12012930178},{"date":"2024-05-17","current":17.127225,"twenty":-52.492457,"median":29.110225,"eighty":46.400692,"marketCap":12767387101},{"date":"2024-05-24","current":17.329127,"twenty":-52.492457,"median":28.924568,"eighty":45.817215,"marketCap":12917894069},{"date":"2024-05-31","current":17.283882,"twenty":-52.492457,"median":28.845467,"eighty":45.631052,"marketCap":12884165886},{"date":"2024-06-07","current":17.6187,"twenty":-52.492457,"median":28.618711,"eighty":45.300146,"marketCap":13133754440},{"date":"2024-06-14","current":18.909713,"twenty":-52.564683,"median":28.448595,"eighty":45.014977,"marketCap":14096131927},{"date":"2024-06-21","current":18.810172,"twenty":-52.636909,"median":28.254893,"eighty":44.814222,"marketCap":14021929925},{"date":"2024-06-28","current":18.505517,"twenty":-52.853586,"median":28.029696,"eighty":44.545997,"marketCap":13794826826},{"date":"2024-07-05","current":17.392472,"twenty":-52.853586,"median":27.883789,"eighty":44.45557,"marketCap":12965113525},{"date":"2024-07-12","current":18.789057,"twenty":-52.853586,"median":27.625789,"eighty":44.208996,"marketCap":14006190106},{"date":"2024-07-15","current":19.202302,"twenty":-52.853586,"median":27.587568,"eighty":44.133343,"marketCap":14314240843},{"date":"2024-08-02","current":127.521095,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12407164899},{"date":"2024-08-09","current":122.295145,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":11898706108},{"date":"2024-08-16","current":122.097192,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":11879446305},{"date":"2024-08-23","current":124.749758,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12137527661},{"date":"2024-08-30","current":130.470589,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12694135959},{"date":"2024-09-06","current":124.630986,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12125971779},{"date":"2024-09-13","current":125.422797,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12203010990},{"date":"2024-09-20","current":132.271958,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12869400164},{"date":"2024-09-27","current":128.926558,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12543909498},{"date":"2024-10-04","current":132.707454,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12911771730},{"date":"2024-10-11","current":129.401645,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12590133024},{"date":"2024-10-18","current":131.499943,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12794286933},{"date":"2024-10-25","current":129.144306,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":12565095281},{"date":"2024-10-31","current":438.477708,"twenty":-53.175656,"median":27.465673,"eighty":43.695796,"marketCap":14242632908},{"date":"2024-11-08","current":488.35729,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":15862821502},{"date":"2024-11-15","current":461.01545,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":14974703854},{"date":"2024-11-22","current":417.482022,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":13560651027},{"date":"2024-11-29","current":442.392158,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":14369782072},{"date":"2024-12-06","current":444.349383,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":14433356655},{"date":"2024-12-13","current":420.091655,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":13645417136},{"date":"2024-12-20","current":397.731842,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":12919125697},{"date":"2024-12-27","current":412.559304,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":13400751320},{"date":"2025-01-03","current":412.381375,"twenty":-53.191367,"median":27.323117,"eighty":43.655773,"marketCap":13394971812},{"date":"2025-01-10","current":433.73292,"twenty":-53.207078,"median":27.180562,"eighty":43.823852,"marketCap":14088512709},{"date":"2025-01-17","current":429.81847,"twenty":-53.207078,"median":27.180562,"eighty":44.119588,"marketCap":13961363545},{"date":"2025-01-24","current":430.174329,"twenty":-53.207078,"median":27.180562,"eighty":44.284649,"marketCap":13972922559},{"date":"2025-01-31","current":437.52875,"twenty":-53.207078,"median":27.180562,"eighty":44.759202,"marketCap":14211808868},{"date":"2025-02-07","current":444.527312,"twenty":-53.207078,"median":27.180562,"eighty":45.130091,"marketCap":14439136162},{"date":"2025-02-14","current":415.411306,"twenty":-53.207078,"median":27.180562,"eighty":45.522611,"marketCap":13548639743},{"date":"2025-02-21","current":423.540337,"twenty":-53.207078,"median":27.180562,"eighty":45.966163,"marketCap":13813768103},{"date":"2025-02-28","current":434.220817,"twenty":-53.207078,"median":27.180562,"eighty":46.516696,"marketCap":14162111933},{"date":"2025-03-07","current":415.885994,"twenty":-53.209696,"median":27.168166,"eighty":47.237523,"marketCap":13564121691},{"date":"2025-03-14","current":401.764027,"twenty":-53.209696,"median":27.168166,"eighty":47.318409,"marketCap":13103533738},{"date":"2025-03-21","current":359.457462,"twenty":-53.209696,"median":27.168166,"eighty":47.54487,"marketCap":11723705123},{"date":"2025-03-28","current":360.050822,"twenty":-53.209696,"median":27.168166,"eighty":47.729411,"marketCap":11743057558},{"date":"2025-04-04","current":370.612629,"twenty":-53.209696,"median":27.168166,"eighty":48.105099,"marketCap":12087530901},{"date":"2025-04-11","current":327.356688,"twenty":-53.207078,"median":27.180562,"eighty":48.204584,"marketCap":10676738389},{"date":"2025-04-17","current":342.546703,"twenty":-53.207078,"median":27.180562,"eighty":48.30276,"marketCap":11172160725},{"date":"2025-04-25","current":349.904367,"twenty":-53.209696,"median":27.168166,"eighty":48.304069,"marketCap":11412130919},{"date":"2025-05-02","current":564.51072,"twenty":-53.209696,"median":27.168166,"eighty":48.393956,"marketCap":12007143006},{"date":"2025-05-09","current":543.579321,"twenty":-52.564683,"median":27.496923,"eighty":48.460691,"marketCap":11561932157},{"date":"2025-05-16","current":571.154163,"twenty":15.632391,"median":27.625789,"eighty":48.737881,"marketCap":12148449057},{"date":"2025-05-23","current":587.080228,"twenty":15.726225,"median":27.883789,"eighty":49.007354,"marketCap":12487196442},{"date":"2025-05-30","current":601.004158,"twenty":15.826258,"median":28.029696,"eighty":49.252879,"marketCap":12783358441},{"date":"2025-06-06","current":611.924888,"twenty":15.885314,"median":28.339221,"eighty":49.434802,"marketCap":13015642362},{"date":"2025-06-13","current":629.944092,"twenty":15.934986,"median":28.478966,"eighty":49.660105,"marketCap":13398910831},{"date":"2025-06-20","current":621.298514,"twenty":15.990815,"median":28.671445,"eighty":49.822312,"marketCap":13215019394},{"date":"2025-06-27","current":644.414059,"twenty":16.096118,"median":28.856014,"eighty":50.382952,"marketCap":13706687026},{"date":"2025-07-03","current":622.936624,"twenty":16.116941,"median":28.993122,"eighty":50.591002,"marketCap":13249861982},{"date":"2025-07-11","current":640.136773,"twenty":16.200713,"median":29.581278,"eighty":51.047771,"marketCap":13615709157},{"date":"2025-07-18","current":627.395921,"twenty":16.252966,"median":30.035802,"eighty":51.822721,"marketCap":13344711249},{"date":"2025-07-25","current":641.501864,"twenty":16.33326,"median":30.242404,"eighty":52.761862,"marketCap":13644744647},{"date":"2025-08-01","current":16.792668,"twenty":16.378635,"median":30.24819,"eighty":52.992543,"marketCap":14624230499},{"date":"2025-08-08","current":17.534873,"twenty":16.546711,"median":30.24819,"eighty":52.992543,"marketCap":15270594539},{"date":"2025-08-15","current":19.319752,"twenty":16.607924,"median":30.24819,"eighty":52.992543,"marketCap":16824992653},{"date":"2025-08-22","current":19.402718,"twenty":16.798469,"median":30.24819,"eighty":52.992543,"marketCap":16897244826},{"date":"2025-08-29","current":18.768144,"twenty":16.870655,"median":30.24819,"eighty":52.992543,"marketCap":16344613336},{"date":"2025-09-05","current":19.158306,"twenty":16.99751,"median":30.268023,"eighty":53.052464,"marketCap":16684393828},{"date":"2025-09-12","current":19.321995,"twenty":17.085907,"median":30.24819,"eighty":52.992543,"marketCap":16826945414},{"date":"2025-09-19","current":19.283875,"twenty":17.161262,"median":30.24819,"eighty":52.992543,"marketCap":16793748470},{"date":"2025-09-26","current":18.310712,"twenty":17.193493,"median":30.24819,"eighty":52.992543,"marketCap":15946250000},{"date":"2025-10-03","current":19.34666,"twenty":17.274387,"median":30.24819,"eighty":52.992543,"marketCap":16848425790},{"date":"2025-10-10","current":19.003586,"twenty":17.291711,"median":30.24819,"eighty":52.992543,"marketCap":16549653288},{"date":"2025-10-17","current":19.577618,"twenty":17.328736,"median":30.24819,"eighty":52.992543,"marketCap":17049560219},{"date":"2025-10-24","current":20.02608,"twenty":17.356711,"median":30.24819,"eighty":52.992543,"marketCap":17440112509},{"date":"2025-10-31","current":15.211911,"twenty":17.362586,"median":30.24819,"eighty":52.992543,"marketCap":18080618265},{"date":"2025-11-07","current":17.376278,"twenty":17.372241,"median":30.24819,"eighty":52.992543,"marketCap":20653148355},{"date":"2025-11-14","current":17.410964,"twenty":17.400499,"median":30.24819,"eighty":52.992543,"marketCap":20694376123},{"date":"2025-11-21","current":16.80808,"twenty":17.400499,"median":30.24819,"eighty":52.992543,"marketCap":19977798257},{"date":"2025-11-28","current":17.254049,"twenty":17.411313,"median":30.24819,"eighty":52.992543,"marketCap":20507869555},{"date":"2025-12-05","current":16.593354,"twenty":17.411313,"median":30.24819,"eighty":52.992543,"marketCap":19722578743},{"date":"2025-12-12","current":15.873197,"twenty":17.411313,"median":30.24819,"eighty":52.992543,"marketCap":18866611758},{"date":"2025-12-19","current":16.073057,"twenty":17.411313,"median":30.24819,"eighty":52.992543,"marketCap":19104162228},{"date":"2025-12-26","current":16.590051,"twenty":17.411313,"median":30.24819,"eighty":52.992543,"marketCap":19718652289},{"date":"2026-01-02","current":16.314211,"twenty":17.411313,"median":30.24819,"eighty":52.992543,"marketCap":19390793375},{"date":"2026-01-09","current":17.495203,"twenty":17.426189,"median":30.24819,"eighty":52.992543,"marketCap":20794500701},{"date":"2026-01-16","current":17.382885,"twenty":17.442549,"median":30.24819,"eighty":52.992543,"marketCap":20661001263},{"date":"2026-01-23","current":17.353153,"twenty":17.454595,"median":30.24819,"eighty":52.992543,"marketCap":20625663177},{"date":"2026-01-30","current":16.695762,"twenty":17.454595,"median":30.24819,"eighty":52.992543,"marketCap":19844298819},{"date":"2026-02-06","current":16.973254,"twenty":17.454595,"median":30.24819,"eighty":52.992543,"marketCap":20174120960},{"date":"2026-02-13","current":15.583655,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"marketCap":20050709464},{"date":"2026-02-20","current":15.735238,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"marketCap":20245743660},{"date":"2026-02-27","current":15.481568,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"marketCap":19919359903},{"date":"2026-03-06","current":15.054661,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"marketCap":19370079922},{"date":"2026-03-13","current":14.234876,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"marketCap":18315303146},{"date":"2026-03-20","current":14.377178,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"marketCap":18498396473},{"date":"2026-03-24","current":13.990487,"twenty":17.493061,"median":30.24819,"eighty":52.992543,"marketCap":18000860258}],"updateTime":1774499309805},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INCY\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593102502","title":"Japan Approves Incyte's Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2593102502","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593102502?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:44","pubTimestamp":1766389457,"startTime":"0","endTime":"0","summary":"Incyte Biosciences Japan has received approval from Japan's Ministry of Health, Labour and Welfare  for Minjuvi  in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma . This marks the first regulatory approval for Minjuvi in Japan and represents the first dual-targeted CD19 and CD20 immunotherapy combination for this indication in the country. The approval is based on results from the pivotal Phase 3 inMIND trial, which demonstrated significant improvement in progression-free survival for patients treated with the combination therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news bri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDLbk6p2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4550","BK4585","BK4588","INCY","BK4139"],"gpt_icon":0},{"id":"2593102526","title":"Incyte Japan Announces Approval of Minjuvi® (Tafasitamab) in Combination With Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2593102526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593102526?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:44","pubTimestamp":1766389440,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUAB1VQHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","INCY","BK4550","BK4588","BK4532","BK4139"],"gpt_icon":0},{"id":"2593010254","title":"Japan Approves Incyte’s Zynyz as First-Line Treatment for Advanced Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2593010254","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593010254?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:42","pubTimestamp":1766389333,"startTime":"0","endTime":"0","summary":"Incyte Biosciences Japan has received approval from the Japan Ministry of Health, Labour and Welfare  for Zynyz  in combination with carboplatin and paclitaxel as a first-line treatment for advanced squamous cell carcinoma of the anal canal . This marks the first regulatory approval for Zynyz in Japan and follows its earlier approval by the U.S. FDA for the same indication. The approval is based on Phase 3 trial data demonstrating a significant reduction in the risk of disease progression or death compared to chemotherapy alone. Incyte has also submitted a marketing authorization application for retifanlimab to the European Medicines Agency.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original conten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL3GrkZd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4550","INCY","BK4139","BK4532"],"gpt_icon":0},{"id":"2593547102","title":"Incyte Japan Announces Approval of Zynyz® (Retifanlimab) for the First-Line Treatment of Advanced Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2593547102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593547102?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:42","pubTimestamp":1766389320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA7TPLKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INCY","BK4588","BK4139","BK4532","BK4550","BK4585"],"gpt_icon":0},{"id":"1116376596","title":"Weekly Winners｜SanDisk, Moderna Rocket Around 15% Each; Carnival Rises over 12%; Micron Rallies More Than 10%; AppLovin Gains 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116376596","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116376596?lang=en_us&edition=fundamental","pubTime":"2025-12-21 11:16","pubTimestamp":1766286970,"startTime":"0","endTime":"0","summary":"This week, which stocks lagged or dragged? Weekly Winners column keeps up with market trends, helping Tigers sort out the week's hottest sectors, stock winners and important news.Below are the top 10...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCLH","CCL","LRCX","APP","INCY","ALB","SNDK","MRNA","CMCSA","MU"],"gpt_icon":1},{"id":"2592190981","title":"Incyte Corp. Stock Advances 5.5%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190981","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190981?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:34","pubTimestamp":1766180040,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Incyte Corp. rose 5.5% to $102.69 on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.9% to 6,834.50 and the Dow Jones Industrial Average rising 0.4% to 48,134.89.Incyte Corp. closed 6.0% short of its 52-week high of $109.28, which the company achieved on November 12th.The stock demonstrated a mixed performance when compared to some of its peers, as Alnylam Pharmaceuticals Inc. rose 1.1% to $400.23, Bio-Techne Corp. rose 2.0% to $58.27, and BioMarin Pharmaceutical Inc. rose 17.71% to $61.15.Trading volume totaled 5.9 million, compared to the 50-day average of 2.3 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2592182922","title":"First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182922","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182922?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:28","pubTimestamp":1766093296,"startTime":"0","endTime":"0","summary":"In mid-December 2025, Incyte announced that the European Commission approved Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory Grade 1–3a follicular lymphoma after at least one prior systemic therapy.\nThis creates the first approved CD19/ CD20 dual-targeted, chemotherapy-free immunotherapy regimen for eligible follicular lymphoma patients in Europe, meaningfully broadening Incyte’s oncology footprint in a key market.\nWe’ll now examine how this new...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/first-chemotherapy-free-cd19cd20-lymphoma-regimen-in-europe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/first-chemotherapy-free-cd19cd20-lymphoma-regimen-in-europe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4550","BK4585","BK4532","INCY","BK4588","BK4139"],"gpt_icon":0},{"id":"2592181433","title":"Incyte EVP Michael James Morrissey Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592181433","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592181433?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:11","pubTimestamp":1766092297,"startTime":"0","endTime":"0","summary":"Michael James Morrissey, EVP, Head of Tech. Operations at Incyte Corporation, has reported a disposal of common shares of Incyte Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL3R2jz2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Incyte EVP Michael James Morrissey Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4550","INCY","BK4585","BK4139"],"gpt_icon":0},{"id":"2592948169","title":"BRIEF-Incyte Announces European Commission Approval Of Minjuvi (Tafasitamab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592948169","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592948169?lang=en_us&edition=fundamental","pubTime":"2025-12-18 04:26","pubTimestamp":1766003215,"startTime":"0","endTime":"0","summary":"BRIEF-Incyte Announces European Commission Approval Of Minjuvi (Tafasitamab)Dec 17 (Reuters) - Incyte Corp INCY.O:INCYTE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF MINJUVI (TAFASITAMAB) FOR THE TREATME","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA1DJQZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4532","INCY","BK4550","BK4585"],"gpt_icon":0},{"id":"2592191460","title":"BUZZ-Incyte up after European Commission expands use of cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2592191460","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592191460?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:40","pubTimestamp":1765989636,"startTime":"0","endTime":"0","summary":"BUZZ-Incyte up after European Commission expands use of cancer drug** Shares of drugmaker Incyte INCY.O rise 1.9% to $98.83** Incyte says that the European Commission has approved its cancer drug Minjuvi in combination with lenalidomide and rituximab ** The new approval expands the use for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy** FL is a type of cancer that begins in the lymph system, a part of the immune system** Minjuvi was already approved by the EC in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma** Including session moves, stock up 42.2% YTD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4N3XN1GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4532","BK4550","INCY","BK4139"],"gpt_icon":0},{"id":"2592148999","title":"EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592148999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592148999?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:20","pubTimestamp":1765988419,"startTime":"0","endTime":"0","summary":"Incyte Corporation has announced that the European Commission  has approved Minjuvi  in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma  after at least one prior systemic therapy. This marks a significant advance as it introduces a chemotherapy-free, CD19- and CD20-dual-targeted immunotherapy option for these patients in Europe. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use  and is based on data from the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival compared to placebo. This is the second EC-approved indication for Minjuvi.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLbxXF21:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","INCY","BK4550","BK4588","BK4532","BK4139"],"gpt_icon":0},{"id":"2592117099","title":"Incyte Announces European Commission Approval of Minjuvi® (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592117099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592117099?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:20","pubTimestamp":1765988400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA1DJQZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4532","BK4588","INCY","BK4550"],"gpt_icon":0},{"id":"2591624736","title":"Incyte Corp. Stock Advances 3.4%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591624736?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:35","pubTimestamp":1765834500,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Incyte Corp. rallied 3.4% to $98.64 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.2% to 6,816.51 and Dow Jones Industrial Average falling 0.1% to 48,416.56.Incyte Corp. closed 9.7% short of its 52-week high of $109.28, which the company achieved on November 12th.The stock outperformed some of its peers, as Alnylam Pharmaceuticals Inc. fell 1.5% to $391.50, Bio-Techne Corp. rose 0.3% to $58.69, and BioMarin Pharmaceutical Inc. fell 2.23% to $52.12.Trading volume totaled 2.8 million, compared to the 50-day average of 2.3 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2591689088","title":"Incyte EVP & Chief Scientific Officer Patrick A. Mayes Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591689088","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591689088?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:02","pubTimestamp":1765573343,"startTime":"0","endTime":"0","summary":"Patrick A. Mayes, Executive Vice President and Chief Scientific Officer of Incyte Corporation, reported a disposal of common shares of Incyte Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLNwcZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Incyte EVP & Chief Scientific Officer Patrick A. Mayes Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4139","BK4588","BK4585","INCY","BK4532"],"gpt_icon":0},{"id":"2591688182","title":"Incyte: on December 10, , HervÉ Hoppenot Notified That He Was Retiring From the Company’s Board of Directors, Effective Immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2591688182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591688182?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:36","pubTimestamp":1765557385,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","INCY","BK4139","BK4550","BK4532","BK4585"],"gpt_icon":0},{"id":"2590501614","title":"Incyte Announces Resignation of Board Member Hervé Hoppenot","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501614","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501614?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:30","pubTimestamp":1765546221,"startTime":"0","endTime":"0","summary":"Incyte Corporation announced that Hervé Hoppenot has resigned from its Board of Directors, effective immediately. Hoppenot previously served as Chairman and CEO and had been acting as an advisor to the CEO during a transition period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire  on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL9FGpsm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4588","BK4532","BK4585","BK4139","BK4550"],"gpt_icon":0},{"id":"2590013065","title":"Incyte Announces Change to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590013065","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590013065?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:30","pubTimestamp":1765546200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA54YWR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","BK4588","BK4550","BK4139","INCY","BK4585"],"gpt_icon":0},{"id":"2590548415","title":"Incyte's Blood Cancer Drug Program 'Looks Very Viable' Amid Development Challenges, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590548415","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590548415?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:14","pubTimestamp":1765473283,"startTime":"0","endTime":"0","summary":"Incyte  is seeing results from its INCA033989 blood cancer drug program that seem to indicate the drug \"looks very viable, safe\" and may have \"unique disease-modifying properties,\" RBC Capital Markets said in a note Thursday, following meetings with the company's senior management.However, optimizing the drug's dosing levels, its administration, and the design of a phase 3 trial may \"be slightly more tedious than earlier Street exuberance had considered,\" RBC said.Incyte recently released updated clinical data from two phase 1 studies assessing the safety, tolerability and efficacy of INCA033989 to treat people with mutCALR-expressing myeloproliferative neoplasms.RBC said that it still believes the program has a good probability of success but a \"smaller ultimate opportunity than consensus.\"The investment firm said Incyte's shares \"approximately fairly reflect [near-term] cash flows.\"RBC has a sector perform rating on Incyte and an $84 price target.Price: 95.75, Change: +0.58, Percent ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4550","BK4588","INCY","BK4532","BK4585","BK4139"],"gpt_icon":0},{"id":"2590753385","title":"Why Incyte (INCY) Is Down 6.2% After Breakthrough Status for INCA033989 And Promising Phase 1 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2590753385","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590753385?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:19","pubTimestamp":1765376362,"startTime":"0","endTime":"0","summary":"In early December 2025, Incyte reported that its mutant calreticulin-targeted antibody INCA033989 received FDA Breakthrough Therapy designation for certain essential thrombocythemia patients and released Phase 1 data showing encouraging responses and tolerability in myeloproliferative neoplasms.\nBy pairing this regulatory milestone with early signs of disease-modifying activity in myelofibrosis, INCA033989 is emerging as a potential new pillar in Incyte’s hematology franchise beyond...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/why-incyte-incy-is-down-62-after-breakthrough-status-for-inc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/why-incyte-incy-is-down-62-after-breakthrough-status-for-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["INCY","BK4532","BK4139","BK4588","BK4550","BK4585"],"gpt_icon":0},{"id":"2590136661","title":"Incyte Presents Updated Positive Data at Ash 2025 Reinforcing the Potential of Inca033989, Its First-in-Class Mutcalr-Targeted Monoclonal Antibody, in Patients With Essential Thrombocythemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2590136661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590136661?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:35","pubTimestamp":1765229701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE1E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INCY","BK4585","BK4588","BK4139","BK4550","BK4532"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":199,"code":"91000000","status":"200"}]}}